PHARMA BIOTECH


Most companies need to de-risk early stage R&D.


How to do this when the number of opportunities for new R&D approaches has never been larger?


Whole institutes now specialise in pproaches that only twenty years ago barely existed. No company can provide equivalent expertise in-house with such
 



Our expertise can help:


  1. avoid the cost of buying in new, complex technologies.

  2. remove lag-times associated with training staff in new methods to achieve  only an elementary understanding.


life science consultancy


Assistance for

pharma & biotech




  1. reduce the number of experiments required to reach a stop/go decision.


  1. manage the selection and out-sourcing of non-core expertise

  2. select the appropriate insourcing of domain specialists